63. 特発性血小板減少性紫斑病 ［臨床試験数：311，薬物数：185（DrugBank：39），標的遺伝子数：43，標的パスウェイ数：132］
Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||ChiCTR1900027735||2020-01-01||2019-11-24||Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP)||Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP)||Adult newly diagnosed immune thrombocytopenia||Study group:Dexamethasone 40mg/d×4d, recombinant human thrombopoietin (rhTPO) 300U/Kg subcutaneous injection, once/d×14d, if PLT>100×109/L or PLT increase =50×109/L during treatment period RhTPO drug was discontinued; rhTPO and dexamethasone were replaced with prednisone 0.5mg~1mg/kg once a day, 0.2mg/kg per week, and the drug was stopped wit;Control group:Dexamethasone 40mg/d×4d, if the PLT>100×10^9/L or PLT increase =50×10^9/L during the treatment period, dexamethasone was replaced with prednisone 0.5mg~ 1mg/kg orally every day, reduce 0.2mg/kg per week, and quickly reduce the dose within 6~8 weeks.;||Department of Hematology, Anhui Provincial Hospital||NULL||Pending||18||80||Both||Study group:30;Control group:30;||Phase 4||China|
|October 1, 2016||19/9/2016||Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone||Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With 3 Cycles Pulses of High-dose Dexamethasone (HD-DXM)||ITP;Croticosteroid Therapy||Drug: High dose Dexamethasone pulses;Drug: Prednisone||Isfahan University of Medical Sciences||Adibvira||Completed||18 Years||N/A||All||36||Phase 2/Phase 3||Iran, Islamic Republic of|
|September 2010||17/5/2011||High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)||High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial||Purpura, Thrombocytopenic, Idiopathic||Drug: Prednisone;Drug: Dexamethasone||Shandong University||Chinese Academy of Medical Sciences;Peking Union Medical College Hospital;Ruijin Hospital;Wuhan Union Hospital, China;Tongji Hospital;Shandong University of Traditional Chinese Medicine;Anhui Provincial Hospital;Zhejiang Provincial Hospital of TCM;Second Hospital of Shanxi Medical University;Xinjiang Uygur Autonomous Region People's Hospital;Shenzhen Second People's Hospital||Completed||18 Years||80 Years||Both||261||Phase 4||China|
|19/06/2008||11/04/2008||Randomized study for the treatment of primary Immune Thrombocytopenic Purpura (ITP) in newly diagnosed untreated adult patients. Comparison of standard dose prednisone versus high-dose Dexamethasone. GIMEMA Protocol ITP0207 - GIMEMA ITP0207||Randomized study for the treatment of primary Immune Thrombocytopenic Purpura (ITP) in newly diagnosed untreated adult patients. Comparison of standard dose prednisone versus high-dose Dexamethasone. GIMEMA Protocol ITP0207 - GIMEMA ITP0207||ITP Primary Immune Thrombocytopenic Purpura in newly diagnosed untreated adult patients |
MedDRA version: 9.1;Level: LLT;Classification code 10021245;Term: Idiopathic thrombocytopenic purpura
|Product Name: Dexamethasone|
INN or Proposed INN: Dexamethasone
Product Name: Prednisone
INN or Proposed INN: Prednisone
|G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|February 2004||8/9/2005||A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone||A Randomized Trial Comparing Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine,and Prednisone) in Subjects With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment||Idiopathic Thrombocytopenic Purpura (ITP)||Drug: Rituximab||Weill Medical College of Cornell University||Genentech, Inc.||Withdrawn||12 Years||N/A||All||0||Phase 2||United States|